Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed Salmon-Durie stage II or III multiple myeloma~  * Untreated disease OR patient underwent prior therapy for this cancer that lasted no more than 2 weeks~* Measurable paraprotein in serum or urine (serum free-lite assay measurement allowed)~* No evidence of cord compression requiring concurrent steroids~PATIENT CHARACTERISTICS:~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 methods of contraception, including ≥ 1 highly effective method, 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment~* No known HIV positivity~* No peripheral neuropathy ≥ grade 2~* No hypersensitivity to bortezomib, boron, or mannitol~PRIOR CONCURRENT THERAPY:~* No prior bortezomib~* More than 28 days since prior regimens with a duration of \> 1 week but ≤ 2 weeks~* No steroids within 14 days prior to study entry~* No concurrent corticosteroids except for the treatment of a nonmalignant condition~  * May not exceed the equivalent dose of prednisone 10 mg/day~* No concurrent chemotherapy, immunotherapy, radiotherapy, or surgery~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib and Thalidomide (Type: EXPERIMENTAL): The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).